A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus.

Michael SchroeterBenjamin BergerFranz BlaesTim HagenackerSebastian JanderJulia KaiserPetra KalischewskiDe-Hyung LeeTobias RuckUlrike ScharaPeter UrbanAndreas Meisel

Published in: Journal of central nervous system disease (2021)

We suggest a sum score to define treatment refractory state in generalised myasthenia gravis. Beyond clarifying the indication of eculizumab, this easy-to-handle score facilitates clinical decision making and offers new inclusion criteria for clinical studies that explore new therapeutic perspectives in myasthenia gravis treatment.

Keyphrases

myasthenia gravis
decision making
bone marrow
mesenchymal stem cells
replacement therapy